All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract

Clinical Efficacy and Safety Evaluation of Ulinastatin Combined with Octreotide in the Treatment of Patients with Severe Acute Pancreatitis

Author(s): Q. DING, YUXIA YAO1, HUIBO WU1, BINBIN XIA AND H. CHENG
Department of Pharmacy, 1Department of Digestive System, Beijing Luhe Hospital Captial Medical Univeisity, No. 82, Xinhua South Road, Tongzhou District, Beijing, China

Correspondence Address:
H. CHENG, Department of Pharmacy, Beijing Luhe Hospital Captial Medical Univeisity, No. 82, Xinhua South Road, Tongzhou District, Beijing, China; E-mail: [email protected]


To investigate the therapeutic efficacy and safety of the combination of ulinastatin and octreotide in the treatment of patients with severe acute pancreatitis. A total of 224 acute pancreatitis patients were selected in our hospital from January 2017 to December 2019 as the subjects of this retrospective study. Among them, observation group (n=112) and control group (n=112). Both groups were treated with conventional basal therapy, the control group treated with octreotide, while the observation group was treated with ulinastatin for 5-7 d in addition of the control group. Serum was used to measure the levels of liver function indicators, clinical efficacy, symptom improvement and complications before and after treatment in both groups. The results showed that the efficacy rate (significant rate+improvement rate) of the treatment group after 5-7 d of treatment was 85.14 %, which was 61.61 % higher than that of the control group; the time for abdominal distension relief, disappearance of pancreatic oedema, disappearance of abdominal pain, return of white blood cells to normal and return of amylase to normal after 5-7 d of treatment was shorter in the treatment group than that of the control group; the levels of transaminase and total bilirubin in the two groups were not statistically significant before treatment (p>0.05); 5-7 d after treatment, the levels of transaminase and total bilirubin in the two groups were significantly lower than those before treatment (p<0.05) and compared with the control group, the levels of transaminase and total bilirubin in the treatment group were significantly lower (p<0.05); the hospital stay time was significantly lower in the treatment group than in the control group. The difference was statistically significant (p<0.05). The combination of octreotide and ulinastatin treatment has a good therapeutic effect on patients with acute severe pancreatitis, helps to reduce the level of liver function indicators and the safety of the drugs is relatively high, so it is worth promoting and applying.

Full-Text | PDF